Leadership Overview
Daiichi Sankyo has 10 executives leading key functions including strategy, financial oversight, clinical development, and global operations.
Focused on advancing pharmaceutical innovation, Daiichi Sankyo delivers life-saving medicines and cutting-edge drug discovery methods to patients across more than 30 countries worldwide.
Focused on advancing pharmaceutical innovation, Daiichi Sankyo delivers life-saving medicines and cutting-edge drug discovery methods to patients across more than 30 countries worldwide.
Leadership Roles at Daiichi Sankyo
Hiroyuki Okuzawa - Representative Director, President and Chief Executive Officer
Hiroyuki Okuzawa, the Representative Director, President and Chief Executive Officer at Daiichi Sankyo, directs the overarching corporate strategy and global pharmaceutical mission. Overseeing the expansion of innovative drug discovery, the Chief Executive Officer ensures alignment between research initiatives and patient needs across international markets. This leadership role involves managing complex stakeholder relationships and driving long-term growth through advanced therapeutic development. By prioritizing sustainable medicine production, Hiroyuki Okuzawa directly impacts the company's ability to address unmet medical needs on a global scale. The Chief Executive Officer maintains rigorous standards for operational excellence while navigating the evolving regulatory landscape of the pharmaceutical industry. Through strategic resource allocation, Okuzawa secures the competitive position of the organization within the global healthcare sector, fostering a culture of scientific advancement and operational efficiency that defines the current trajectory of the firm.

Kazuki Mori - Chief of Staff To Chief Executive Officer
Kazuki Mori, the Chief of Staff To Chief Executive Officer at Daiichi Sankyo, manages the executive office operations and facilitates strategic communication for the leadership team. Overseeing the prioritization of executive initiatives, the Chief of Staff To Chief Executive Officer ensures that the strategic vision of the firm is effectively translated into actionable tasks across all departments. This leadership role involves coordinating high-level meetings and managing the flow of information to support informed decision-making by the executive leadership. By streamlining the administrative functions of the office, Kazuki Mori directly impacts the efficiency of the company's strategic execution. The Chief of Staff To Chief Executive Officer maintains a focus on organizational alignment and the successful implementation of corporate goals. Through the management of executive priorities, Mori secures the operational focus required for the company to continue its mission of providing innovative pharmaceutical solutions to patients globally.
Bruno Luiz de Vicente Cadastro - Chief Financial Officer
Bruno Luiz de Vicente Cadastro, the Chief Financial Officer at Daiichi Sankyo, manages the fiscal health and capital allocation strategies of the organization. Overseeing global financial reporting and risk management, the Chief Financial Officer ensures the stability of investments in drug discovery and manufacturing infrastructure. This leadership role involves optimizing capital structures to support the development of innovative medicines across diverse international markets. By implementing robust financial controls, Bruno Luiz de Vicente Cadastro directly impacts the efficiency of resource distribution throughout the pharmaceutical supply chain. The Chief Financial Officer maintains transparency with investors while driving profitability through disciplined cost management and strategic financial planning. Through the analysis of market trends and economic indicators, Cadastro secures the financial foundation necessary for the company to continue delivering advanced therapeutic solutions to patients worldwide, ensuring long-term viability and growth in the competitive global pharmaceutical landscape.
Tomohiro Kodama - Senior Executive Officer, Head of Global Corporate Planning and Management, Chief Financial Officer
Tomohiro Kodama, the Senior Executive Officer, Head of Global Corporate Planning and Management, Chief Financial Officer at Daiichi Sankyo, architects the long-term corporate strategy and oversees global financial management. Overseeing the alignment of corporate planning with fiscal objectives, the Senior Executive Officer, Head of Global Corporate Planning and Management, Chief Financial Officer ensures that strategic investments support the development of innovative medicines. This leadership role involves synthesizing market data to guide organizational growth and resource allocation across international territories. By integrating financial planning with corporate vision, Tomohiro Kodama directly impacts the company's ability to scale operations and maintain market leadership. The Senior Executive Officer, Head of Global Corporate Planning and Management, Chief Financial Officer maintains a focus on sustainable growth and operational efficiency. Through the execution of strategic initiatives, Kodama secures the financial and operational health of the firm, ensuring the successful delivery of advanced pharmaceutical solutions to patients worldwide.
Chloe Stern - Manager, Chief Financial Officer Planning Department
Chloe Stern, the Manager, Chief Financial Officer Planning Department at Daiichi Sankyo, executes detailed financial forecasting and budgetary planning to support the organization's pharmaceutical objectives. Overseeing the analytical processes within the finance department, the Manager, Chief Financial Officer Planning Department ensures that departmental budgets align with the broader fiscal strategy of the company. This leadership role involves providing data-driven recommendations to senior leadership to optimize spending on drug discovery and development projects. By monitoring financial performance metrics, Chloe Stern directly impacts the accuracy of resource allocation across global operations. The Manager, Chief Financial Officer Planning Department maintains rigorous oversight of financial planning activities to ensure compliance and efficiency. Through the meticulous management of financial data, Stern secures the necessary budgetary support for the company's research and development initiatives, contributing to the overall success of the firm in delivering innovative medicines to patients.
Suthas Thongprasert - President
Suthas Thongprasert, the President at Daiichi Sankyo, directs regional operations and oversees the execution of corporate strategy within specific market territories. Overseeing the implementation of business development initiatives, the President ensures that the company's pharmaceutical portfolio is effectively positioned to meet local healthcare needs. This leadership role involves managing regional teams and fostering partnerships to drive market penetration and growth. By aligning regional activities with the global mission, Suthas Thongprasert directly impacts the company's success in delivering innovative medicines to diverse patient populations. The President maintains focus on operational performance and regulatory compliance within the assigned region. Through the leadership of regional operations, Thongprasert secures the company's competitive standing and contributes to the overall success of the firm in providing advanced drug discovery and delivery methods to patients across the globe, ensuring consistent growth and impact.
Kosuke Itagaki - Chief of Staff & Global System Owner
Kosuke Itagaki, the Chief of Staff & Global System Owner at Daiichi Sankyo, coordinates internal administrative workflows and manages the integrity of global digital systems. Overseeing the integration of enterprise-wide technology platforms, the Chief of Staff & Global System Owner ensures that data-driven insights support the development of innovative pharmaceutical products. This leadership role involves streamlining communication between executive departments to enhance operational agility across regional operations. By maintaining the reliability of critical infrastructure, Kosuke Itagaki directly impacts the speed and accuracy of drug discovery processes. The Chief of Staff & Global System Owner facilitates cross-functional collaboration to align technical capabilities with the broader corporate mission of improving patient outcomes. Through the optimization of internal systems, Itagaki secures the technological backbone required for the company to maintain its leadership position in the global pharmaceutical market, fostering a seamless environment for scientific and operational success.
John Harkins - Senior Director, Chief of Staff, Global Oncology Clinical Development
John Harkins, the Senior Director, Chief of Staff, Global Oncology Clinical Development at Daiichi Sankyo, manages the administrative and strategic execution of oncology-focused clinical trials. Overseeing the coordination of global development teams, the Senior Director, Chief of Staff, Global Oncology Clinical Development ensures that complex research projects meet rigorous safety and efficacy standards. This leadership role involves synchronizing clinical operations across multiple international regions to accelerate the delivery of cancer therapies. By facilitating communication between research scientists and clinical staff, John Harkins directly impacts the efficiency of the drug development pipeline. The Senior Director, Chief of Staff, Global Oncology Clinical Development maintains focus on patient-centric outcomes while navigating the intricacies of global regulatory requirements. Through the management of clinical resources, Harkins secures the successful progression of oncology assets, driving the company's mission to provide transformative treatments for patients battling cancer on a global scale.
Caitlin Barnabo - Global Oncology Medical Affairs Chief of Staff
Caitlin Barnabo, the Global Oncology Medical Affairs Chief of Staff at Daiichi Sankyo, coordinates the strategic activities of the medical affairs division within the oncology sector. Overseeing the integration of medical insights into clinical development programs, the Global Oncology Medical Affairs Chief of Staff ensures that scientific data effectively informs the company's therapeutic strategy. This leadership role involves managing cross-functional projects that bridge the gap between research and clinical application. By facilitating collaboration among medical experts, Caitlin Barnabo directly impacts the quality and relevance of the company's oncology portfolio. The Global Oncology Medical Affairs Chief of Staff maintains focus on evidence-based practices to support the successful launch and adoption of new cancer treatments. Through the coordination of medical affairs initiatives, Barnabo secures the scientific integrity of the company's oncology offerings, ensuring that patients receive the most advanced and effective care possible.
Kosuke Uchida - Director, Chief Marketing Officer Management, Supply Chain and Technical Operations
Kosuke Uchida, the Director, Chief Marketing Officer Management, Supply Chain and Technical Operations at Daiichi Sankyo, manages the intersection of marketing strategy, supply chain logistics, and technical production. Overseeing the alignment of product availability with market demand, the Director, Chief Marketing Officer Management, Supply Chain and Technical Operations ensures that innovative medicines reach patients efficiently across global markets. This leadership role involves optimizing technical operations to maintain high manufacturing standards while supporting marketing initiatives. By streamlining the supply chain, Kosuke Uchida directly impacts the reliability and accessibility of the company's pharmaceutical products. The Director, Chief Marketing Officer Management, Supply Chain and Technical Operations maintains focus on operational excellence to support the company's growth objectives. Through the integration of supply chain and marketing functions, Uchida secures the successful delivery of therapeutic solutions, ensuring that the company meets the needs of patients and healthcare providers worldwide.
Explore Leadership Teams in Manufacturing
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in Phase III clinical trials to treat glabellar (frown) lines, as well as in Phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark,...
Company Leadership
RW
SK
MA
Telix Pharmaceuticals is a global, commercial-stage biopharmaceutical company headquartered in North Melbourne, Australia, publicly listed on the Australian Securities Exchange and Nasdaq under the ticker TLX. The company specializes in the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, commonly referred to as theranostics, which use molecularly targeted radiation to both image and treat cancer. Telix's pipeline is focused on urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma), and bone marrow conditioning. Its lead commercial product, Illuccix, is an approved PSMA-PET/CT imaging agent for prostate cancer with regulatory clearance from the FDA, Australia's TGA, and Health Canada.
Company Leadership KR
CB


Morepen Laboratories is a leading pharmaceutical company specializing in Active Pharmaceutical Ingredients (APIs) and finished formulations. With a commitment to quality and innovation, the company offers a wide range of healthcare, grooming, and OTC products under trusted brands like Dr. Morepen and Gubb World, catering to over 100 million consumers. Morepen has a robust global presence, exporting to over 80 countries and holding certifications from regulatory authorities such as USFDA and WHO GMP. The company is dedicated to enhancing lives through its extensive research and development efforts and state-of-the-art manufacturing facilities.
Company Leadership VS
KS
PM
Indivior is a global pharmaceutical company dedicated to developing medicines that treat opioid use disorder, alcohol use disorder, and serious mental illnesses. The company researches, develops, manufactures, and commercializes innovative therapies that improve patient outcomes and expand access to evidence-based treatment. With operations across multiple countries, Indivior focuses on addressing addiction as a chronic disease through science-driven solutions and patient-centered care.
Company Leadership
TP
JB
